How Treatment Advances Affect Prevention's Cost-Effectiveness

Pinkerton SD , Holtgrave DR How HIV treatment advances affect the cost-effectiveness of prevention Med Decis Making. 2000,20:89-94

Koplan JP. Benefits, risks and costs of immunization programmes. In Ciba Foundation Symposium 110, The Value of Preventive Medicine. London , U.K.: Pitman, 1985

Office of Technology Assessment , U.S. Congress Cost-Effectiveness of Influenza Vaccination. Washington, DC. Office of Technology Assessment , December 1981.

Sisk JE , Moskowitz AJ , Whang W , et al Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people JAMA. 1997,278:1333-9.

Tucker AW , Haddix AC , Bresee JS , Holman RC , Parashar UD , Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998;279: 1371-6.

Krahn M , Guasparini R , Sherman M , Detsky AS Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program for the United States Am J Public Health. 1998;88:1638-44.

Goldman L , Weinstein MC , Goldman PA , Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition. JAMA. 1991; 265:1145-51.

Toronto Working Group on Cholesterol Policy. Asymptomatic hypercholesterolemia: a clinical policy review . J Clin Epidemiol. 1990;43:1062.

Gross CP , Anderson GF , Powe NR. The relationship between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999 ;340:1881-7.

Varmus, H. Evaluating the burden of disease and spending the research dollars of the National Institutes of Health N Engl J Med 1999;340:1914-5.